South Korea’s antitrust regulator announced on Wednesday, July 17, that it has fined two makers of blood bags a combined 7.7 billion won (US$6.5 million) for colluding to fix their bidding prices for the country’s Red Cross.
Greencross Medical Science and TaeChang Industrial fixed their bids to avoid price competition, according to the Fair Trade Commission (KFTC).
The Commission fined Greencross Medical Science and TaeChang Industrial 5.8 billion won and 1.9 billion won, respectively (US$4.9 million and US$1.6 million, respectively). The Commission has decided to refer Greencross Medical Science and one of its officials to the prosecutors’ office for further investigation.
Full Content: YNA
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh